Tempus AI (TEM) has introduced the next-generation of its agentic AI platform for oncology drug development, Lens, the company said over the weekend.
The platform was designed to help drug development teams to design better clinical trials, target patient subgroups, and generate evidence more quickly, Tempus AI said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.